KRAS Mutation Analysis Prior to EGFR-Directed Therapy for Metastatic Colorectal Cancer: A Review and Cost Analysis

By  

Current Cancer Therapy Reviews, Vol. 6, Iss. 4, 2010-11 ,pp. : 256-261

Bentham Science Publishers

Access to resources Recommend Favorite

Good response to leucovorin and fluorouracil plus oxaliplatin and cetuximab therapy in a patient with metastatic ascending colon cancer harboring a KRAS p.G13D mutation

By Ochiai Takumi   Nishimura Kazuhiko   Watanabe Tomoo   Kitajima Masayuki   Nakatani Akinori   Inou Takashi   Washio Marie   Sakuyama Naoki   Sato Tsuyoshi   Kishine Kenji   Ochi Takanori   Ookubo Satoshi   Futagawa Shunji   Orikasa Hideki   Mashiko Satomi   Nagaoka Isao  

Oncology Letters, Vol. 3, Iss. 2, 2012-02 ,pp. : 269-272

Spandidos Publications

Access to resources Recommend Favorite

Expression and significance of Cx43 and E-cadherin in gastric cancer and metastatic lymph nodes

By Tang Bo  

Medical Oncology, Vol. 28, Iss. 2, 2011-06 ,pp. : 502-508

Humana Press, Inc

Access to resources Recommend Favorite

Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival

By                                

Molecular and Clinical Oncology, Vol. 3, Iss. 5, 2015-01 ,pp. : 1053-1057

Science Publishers

Access to resources Recommend Favorite

Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS

By Tural Deniz   Batur Sebnem   Erdamar Sibel   Akar Emre   Kepil Nuray   Mandel Nil   Serdengeçti Süheyla  

Tumor Biology, Vol. 35, Iss. 2, 2014-02 ,pp. : 1041-1049

Springer Publishing Company

Access to resources Recommend Favorite